Orion Corporation and Newel Health enter into licensing agreement for a digital therapeutic (DTx) ODD-403 (“Rohkea”) in pain
Digital Health Global
JANUARY 29, 2024
As showcased in the ‘ VIRPI ‘ study, ODD-403 marks a statistically significant advancement in chronic pain management. Newel Health is well poised to leverage ODD-403’s compelling clinical findings, underscoring its commitment to delivering validated and impactful digital health solutions.
Let's personalize your content